Brief: Belite Bio Receives EMA Approval To Initiate Tinlarebant Phase 3 Clinical Trial
06/02/2024 07:38
Feb 6 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO INC - RECEIVES EMA APPROVAL TO INITIATE
TINLAREBANT
PHASE 3 CLINICAL TRIAL FOR GA IN FRANCE AND CZECH REPUBLIC
* BELITE BIO INC - TRIAL WILL INITIATE AFTER AGENCY
REQUESTED
PROTOCOL AMENDMENT SPECIFIC TO EU HAS BEEN MADE
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses